Morning sickness drug reintroduced to US


The US Food and Drug Administration (FDA) has approved a drug for morning sickness, 30 years after it was originally removed from the market.

Diclegis (doxylamine succinate and pyridoxine hydrochloride), contains the same active ingredients as Benedictin, which was produced by Merrel Dow and withdrawn from the market in 1983 after a string of lawsuits claiming it caused birth defects.

Rather than fight the litigations, Merrel Dow voluntarily withdrew the product. However, Canadian company Duchesnay continued to market the drug in Canada, under the name Diclectin. Large scale studies have shown the drug to be safe for both mothers and foetuses, so Duchesnay has now decided to expand into the US by applying for approval of its long-release version.

The drug has been approved for use by pregnant women whose morning sickness cannot be controlled through dietary means, such as by eating smaller meals of bland food throughout the day.


Related Content

Chemistry World podcast - January 2014

15 January 2014 Podcast | Monthly

news image

This month, we examine the controversy surrounding the Turin shroud and explore the history of crystallography

Business roundup

26 February 2008 Business

news image

Industry news

Most Read

Higher levels of some metals in e-cigarette smoke

8 September 2014 Research

news image

Scientists call for regulators to help clear smoke and mirrors surrounding vaping safety

Isotope effect produces new type of chemical bond

22 October 2014 Research

news image

Evidence emerges for vibrational bond first proposed 30 years ago

Most Commented

Higher levels of some metals in e-cigarette smoke

8 September 2014 Research

news image

Scientists call for regulators to help clear smoke and mirrors surrounding vaping safety

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines